Autism and cancer evidence: no causal autism change; colorectal review extended
No new replicated causal autism result or official surveillance report was identified. Genetic findings, prenatal or perinatal exposures, environmental associations, diagnostic changes and proposed mechanisms remain separate; no single cause has been established. FDA extended review of zanzalintinib plus atezolizumab for previously treated metastatic colorectal cancer to March 3, 2027 after new safety and efficacy material was deemed a major amendment.
Central finding
- No single autism cause has been established.
- FDA moved the colorectal-cancer review deadline to March 3, 2027.
Evidence and limits
High-quality evidence does not support vaccines as an autism cause, while vaccine safety surveillance remains appropriate for specific adverse outcomes. The cancer combination is not approved and is not a cure. Reporting describes a statistically significant overall-survival result in a broad late-stage group but one missed survival goal in a subgroup; full absolute effects, follow-up and adverse-event data were not newly released.
- Complete absolute survival and adverse-event data were not newly available.
- The therapy is not approved and should not be described as a cure.
Why it matters
The FDA extension allows additional benefit-risk review for a defined metastatic population without overstating interim company or trial claims.
What changed
No autism-causation change occurred; the cancer-review deadline moved three months.
What comes next
Replicated autism evidence; complete trial data; absolute survival benefit; toxicity; peer review; independent replication and FDA action.
U.S. strategic assessment
High interestPatients and families are harmed when preliminary associations or limited treatment results are promoted as established causes or cures.
Objectives
- Protect U.S. security, economic resilience, and citizens using measurable, lawful action.
Strategy
- Use primary records, allied coordination, market evidence, and independent verification to distinguish action from rhetoric.
Outcomes
- No result crossed the publication threshold during the window.
Risks
- Evidence searches are constrained by publication timing and access.
Sources
01Regulatory status, deadline and incomplete efficacy interpretation.